The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review
Objectives: The purpose of this article is to systematically review the use, efficacy, differences between botulinum toxin type A doses and side effects of botulinum toxin type A therapy in patients with trigeminal neuralgia. Material and Methods: The search for the performed reviews was done in...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Lithuanian University of Health Sciences, Faculty of Odontology
2020-06-01
|
| Series: | eJournal of Oral Maxillofacial Research |
| Subjects: | |
| Online Access: | https://www.ejomr.org/JOMR/archives/2020/2/e2/v11n2e2ht.htm |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849686534260785152 |
|---|---|
| author | Anton Rubis Gintaras Juodzbalys |
| author_facet | Anton Rubis Gintaras Juodzbalys |
| author_sort | Anton Rubis |
| collection | DOAJ |
| description | Objectives: The purpose of this article is to systematically review the use, efficacy, differences between botulinum toxin type A doses and side effects of botulinum toxin type A therapy in patients with trigeminal neuralgia.
Material and Methods: The search for the performed reviews was done in PubMed and Cochrane library in English language from January 2010 up to February 2020. Inclusion criteria: full-text studies in English language, in which visual assessment scale (VAS) was present, in which patients with trigeminal neuralgia (TN) were participated and the comparison between botulinum toxin type A (BT-A) and saline was done.
Results: The review included 4 randomized, double-blind, placebo-controlled trials with 8 to 12 weeks follow-up to observe changes in VAS and in frequency of TN attacks, differences between dosages of BT-A in therapy and side effects. Mean VAS of BT-A group decreased by approximately 68% and of palcebo group decreased by approximately 21.6% after the therapy. Mean frequency of TN attacks in 3 studies of BT-A group decreased by 85%, while in palcebo by only 15.9%.
Conclusions: Botulinum toxin type A injection therapy is a safe and effective method in management of trigeminal neuralgia. No differences between dosages of botulinum toxin type A were found. Maximum efficacy was noticed between 6 weeks and 3 months after the procedure. Side effects were mostly facial asymmetry after injection, headaches, haematoma, which disappeared in one week. |
| format | Article |
| id | doaj-art-fa688100f8cc40be9f8aaed4810b0575 |
| institution | DOAJ |
| issn | 2029-283X |
| language | English |
| publishDate | 2020-06-01 |
| publisher | Lithuanian University of Health Sciences, Faculty of Odontology |
| record_format | Article |
| series | eJournal of Oral Maxillofacial Research |
| spelling | doaj-art-fa688100f8cc40be9f8aaed4810b05752025-08-20T03:22:39ZengLithuanian University of Health Sciences, Faculty of OdontologyeJournal of Oral Maxillofacial Research2029-283X2020-06-01112e210.5037/jomr.2020.11202The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature ReviewAnton RubisGintaras JuodzbalysObjectives: The purpose of this article is to systematically review the use, efficacy, differences between botulinum toxin type A doses and side effects of botulinum toxin type A therapy in patients with trigeminal neuralgia. Material and Methods: The search for the performed reviews was done in PubMed and Cochrane library in English language from January 2010 up to February 2020. Inclusion criteria: full-text studies in English language, in which visual assessment scale (VAS) was present, in which patients with trigeminal neuralgia (TN) were participated and the comparison between botulinum toxin type A (BT-A) and saline was done. Results: The review included 4 randomized, double-blind, placebo-controlled trials with 8 to 12 weeks follow-up to observe changes in VAS and in frequency of TN attacks, differences between dosages of BT-A in therapy and side effects. Mean VAS of BT-A group decreased by approximately 68% and of palcebo group decreased by approximately 21.6% after the therapy. Mean frequency of TN attacks in 3 studies of BT-A group decreased by 85%, while in palcebo by only 15.9%. Conclusions: Botulinum toxin type A injection therapy is a safe and effective method in management of trigeminal neuralgia. No differences between dosages of botulinum toxin type A were found. Maximum efficacy was noticed between 6 weeks and 3 months after the procedure. Side effects were mostly facial asymmetry after injection, headaches, haematoma, which disappeared in one week.https://www.ejomr.org/JOMR/archives/2020/2/e2/v11n2e2ht.htmbotulinum a toxinbotulinum neurotoxin atrigeminal neuralgiatrigeminal nerve |
| spellingShingle | Anton Rubis Gintaras Juodzbalys The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review eJournal of Oral Maxillofacial Research botulinum a toxin botulinum neurotoxin a trigeminal neuralgia trigeminal nerve |
| title | The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review |
| title_full | The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review |
| title_fullStr | The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review |
| title_full_unstemmed | The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review |
| title_short | The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review |
| title_sort | use of botulinum toxin a in the management of trigeminal neuralgia a systematic literature review |
| topic | botulinum a toxin botulinum neurotoxin a trigeminal neuralgia trigeminal nerve |
| url | https://www.ejomr.org/JOMR/archives/2020/2/e2/v11n2e2ht.htm |
| work_keys_str_mv | AT antonrubis theuseofbotulinumtoxinainthemanagementoftrigeminalneuralgiaasystematicliteraturereview AT gintarasjuodzbalys theuseofbotulinumtoxinainthemanagementoftrigeminalneuralgiaasystematicliteraturereview AT antonrubis useofbotulinumtoxinainthemanagementoftrigeminalneuralgiaasystematicliteraturereview AT gintarasjuodzbalys useofbotulinumtoxinainthemanagementoftrigeminalneuralgiaasystematicliteraturereview |